Recently, the "2023 Big Health Industry High-Quality Development Conference and the 8th China Pharmaceutical R&D Innovation Summit (PDI)" co-organized by China Pharmaceutical Industry Magazine and Yaozhi.com was held in Chongqing. The organizing committee of the 8th China Pharmaceutical R&D Innovation Summit and the 2023 China Pharmaceutical R&D Strength Ranking Expert Committee selected the "2023 China Pharmaceutical R&D Strength Ranking" series of lists, and GeneCradle won the "China Biopharmaceutical R&D Strength Ranking TOP50".

About GeneCradle

Beijing GeneCradle Technology Co., Ltd. is a national high-tech enterprise with AAV vector delivery technology-mediated gene therapy drug development as its core business. Its mission is to promote China's rare disease gene drugs from basic to clinical and market, benefiting patients and families. The company focuses on the development of gene therapy drugs in the fields of hereditary neuromuscular diseases, genetic metabolic diseases, lysosomal diseases and ophthalmic diseases. By promoting the development and clinical application of rare disease gene drugs, it has a deeper understanding of life and health, and has transitioned gene therapy technology and products from rare diseases to the treatment and rehabilitation of chronic diseases and other major diseases.